SCHEMBL2179300

SCHEMBL2179300

O=C(Br)c1cccc(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.63
KCNK3 O14649 1/20 0.53
KCNK9 Q9NPC2 1/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 2/20 0.52
ERCC5 P28715 1/20 0.52
FEN1 P39748 1/20 0.52
MAOA P21397 2/20 0.49
MAOB P27338 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
KCNMA1 Q12791 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
FLT1 P17948 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL689178 0.83 ATM (0.52) PARP1KCNK3KCNK9MEN1KMT2A
SCHEMBL3173817 0.81 PARP1 (0.68) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL3169530 0.81 PARP1 (0.68) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL29360692 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL104419 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL29637481 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL2163516 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL3444927 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL38766 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A
SCHEMBL28134936 0.79 PARP1 (0.65) PARP1KCNK3KCNK9NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2019-01-31 US disclosed
EP-3400226-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER Emcure Pharmaceuticals Limited (IN) 2018-11-14 EP disclosed
WO-2017134555-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER EMCURE PHARMACEUTICALS LIMITED (IN) 2017-08-10 WO disclosed
CN-102548991-B Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors HOFFMANN LA ROCHE 2015-03-25 CN disclosed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
CN-102781915-A Diacylglycerol acyltransferase inhibitors PIRAMAL LIFE SCIENCES LTD 2012-11-14 CN disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed
US-4698333-A Use of substituted malonic acid derivatives as agents for combating pests BAYER AKTIENGESELLSCHAFT (DE) 1987-10-06 US disclosed
US-4562185-A INSECTICIDES; MITICIDES BAYER AKTIENGESELLSCHAFT (DE) 1985-12-31 US disclosed
EP-0126235-A1 Five-membered nitrogen-containing heterocycles, process for their preparation and their use as pesticides BAYER AG (DE) 1984-11-28 EP disclosed
EP-0108351-A2 Use of substituted malonic-acid derivatives as pesticides BAYER AG (DE) 1984-05-16 EP disclosed
EP-0040408-A1 Beta-lactam compounds and process for production thereof SANRAKU-OCEAN CO., LTD. (JP) 1981-11-25 EP disclosed
EP-0001252-B1 PROCESS FOR THE PREPARATION OF META-HALOBENZOYL HALIDES HOECHST AKTIENGESELLSCHAFT (DE) 1980-08-06 EP disclosed
US-4190600-A IRON/III/ CHLORIDE OR BROMIDE HALOGENATION CATALYST WITH SULFUR COCATALYST HOECHST AKTIENGESELLSCHAFT (DE) 1980-02-26 US disclosed
US-4180525-A OLIGOMERIZING OLEFINS PHILLIPS PETROLEUM COMPANY (US) 1979-12-25 US disclosed
EP-0001252-A1 Process for the preparation of meta-halobenzoyl halides HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-04 EP disclosed
US-4123447-A REACTING (1,5-CYCLOOCTADIENE)BIS(TRIETHYLPHOSPHINE)-NICKEL(O) WITH AN ACYL HALIDE, OLIGOMERIZATION CATALYSTS PHILLIPS PETROLEUM COMPANY (US) 1978-10-31 US disclosed
US-3970671-A XANTHENE, PRESSURE SENSITIVE KANZAKI PAPER MANUFACTURING CO., LTD. (JA) 1976-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031665-A1 DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER IDO1, IDO2, TDO2 PARP1 1505/4885KCNK3 2590/4885KCNK9 4165/4885
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PARP1 2605/4885KCNK3 4252/4885KCNK9 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.